Authors
Latest:
The Role of Postmastectomy Radiotherapy in Locally Advanced Breast Cancer After Pathological Complete Response to Neoadjuvant ChemotherapyExperts examine the case of a previously healthy woman, aged 32 years, presented to the oncology clinic with a 6-month history of left-breast tumor, mastalgia, and swollen axillary nodes.
Latest:
Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic DiseasesA panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.
Latest:
Clinical Pros of Sacituzumab and T-DXdPanelists discuss how sacituzumab shows significant efficacy in triple-negative breast cancer, with improved progression-free and overall survival. It demonstrates particular benefit in pretreated patients and brain metastases cases. Trastuzumab deruxtecan (T-DXd) excels in HER2-positive breast cancer treatment, showing remarkable response rates and survival benefits, including in patients with brain metastases and those who progressed on prior therapies.
Latest:
Expert Commentary on the Product Profile of Fruquintinib in Metastatic CRCJagoda Misniakiewicz, PharmD, discussed implementing fruquintinib into clinical practice and how it's mechanism of action compares with others in the space.
Latest:
Relapsed or Refractory Diffuse Large B-Cell Lymphoma: “Dazed and Confused”This review article written by Meghana Kesireddy, MBBS and Matthew A. Lunning, MD, reviews management and treatment of relapsed/refractory large B-cell lymphoma.
Latest:
Exciting Developments in the Pipeline in HER2+ MBCA multidisciplinary panel of health care professionals and a patient advocate comment on their excitement about novel therapies in the pipeline for HER2-positive metastatic breast cancer.
Latest:
Oncology Peer Review On-The-Go: Current Treatments in Peripheral T-cell LymphomaRobert Stuver, MD, and Zachary D. Epstein-Peterson, MD, spoke with CancerNetwork® about a review article on the treatment of peripheral T-cell lymphoma published in the journal ONCOLOGY®.
Latest:
COVID-19 Vaccination in Patients With Cancer and Recipients of Cellular TherapyFareed Khawaja, MBBS, and colleagues provide a comprehensive overview of COVID-19 vaccine efficacy and safety among patients with cancer in the United States.
Latest:
Vivek Subbiah, MD, on Data from AACR on Resistance Mechanisms to KRAS InhibitorsCancerNetwork® spoke with Vivek Subbiah, MD, during the virtual American Association for Cancer Research Annual Meeting 2021 to discuss the most important data to come out of the meeting regarding therapy for tumors harboring KRAS mutations.
Latest:
Identifying Indications for Neoadjuvant Therapy in CholangiocarcinomaThe recent Hot Topics section focuses on survival rates for patients with cholangiocarcinoma.
Latest:
Key Findings and Conclusions from MARIPOSA-2 TrialThe panelist summarizes the major findings from MARIPOSA-2 and their conclusions about amivantamab regimens improving outcomes in osimertinib-resistant NSCLC.
Latest:
American Oncology Network Names James Gilmore Chief Pharmacy & Procurement OfficerAmerican Oncology Network, LLC (AON) recently announced the appointment of James Gilmore, PharmD, as the organization’s Chief Pharmacy & Procurement Officer.
Latest:
Jhalak Dholakia, MD, Spotlights Ongoing Trial of Neoadjuvant Mirvetuximab Soravtansine in FRα-High Ovarian CancerAn ongoing trial assessing neoadjuvant mirvetuximab soravtansine plus carboplatin in advanced folate receptor α–positive ovarian was reviewed by Jhalak Dholakia, MD, at The Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer.
Latest:
Hereditary vs Familial Pancreatic Cancer: Associated Genetic Syndromes and Clinical PerspectivePancreatic ductal adenocarcinoma is a disease marked by high rates of mortality, with only about 7% of patients surviving 5 years after diagnosis. Here, the authors present a demonstrative case and review the available data on hereditary and familial PDAC.
Latest:
Unmet Needs and Future Directions for GPRC5D Bispecific TherapyPanelists discuss how unmet needs and future directions for GPRC5D bispecific therapy include improving accessibility, managing long-term safety, and exploring combination strategies to enhance treatment efficacy.
Latest:
Use of Immunotherapy in Patients With Cancer During the COVID-19 PandemicThis article discusses the potential implications of using checkpoint inhibitors during the COVID-19 pandemic.
Latest:
Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous RituximabRituximab-subcutaneously is associated with significantly reduced chair time vs rituximab-intravenously in a US oncology setting. Widespread adoption would be expected to improve practice efficiency and patient access to care, and to reduce health care resource burden.
Latest:
Collaborative Education for CAR T-Cell TherapyThe panel concludes its discussion with insights on practices for educating health care teams on CAR T-cell therapy administration, highlighting the evolving role of advanced practice providers.
